odn 1826

ODN 1826 is a 20-mer DNA strand, a TLR9 agonist and an immunostimulant, with anti-tumor and cardioprotective effects, promoting apoptosis, and stimulating the production of NO and iNOS. ODN 1826 is a CpG DNA mimetic that can be used as an adjuvant for synthetic vaccines.

ODN 1826 sodium is a class B CpG ODN (oligodeoxynucleotide) and a TLR9 agonist. It induces the production of NO and iNOS and enhances apoptosis. ODN 1826 sodium boosts immune surveillance and increases the size of atherosclerotic plaques. It exhibits antitumor activity against lung cancer, glioma, and melanoma.

Biotin-labeled ODN 1826 (sodium), a class B CpG oligodeoxynucleotide (ODN), functions as a TLR9 agonist and enables the evaluation of CpG ODN cellular uptake and localization using biotin detection systems and light microscopy.

FITC-labeled ODN 1826 (sodium), a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist, enables the evaluation of CpG ODN cellular uptake and localization via confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

FAM-labeled ODN 1826 sodium is a class B CpG ODN and acts as a TLR9 agonist. The cellular uptake and localization of CpG ODNs by FAM-labeled ODN 1826 sodium can be assessed using confocal laser scanning microscopy or flow cytometry.